SecBot SecBot

ENTA

ENANTA PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· CIK 0001177648 Biotech & Drug Discovery
$10.67 −0.32 (−2.91%)
Nov 16 4:00 PM ET · prev $10.99
Market cap
$326.2M
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
🔒 Subscribers only
1 year
−16.8%
from $12.82 · Nov 17
30 days
−6.5%
from $11.41
52-week range
$10.08–16.85
−37% from high · low Nov 5
Avg volume 20D
259.0K
shares / day
Short interest
1.86M
≈6.4% of shares · −18.0%
Days to cover
7.6
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 11 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better.

  • Short sellersCOVERING

    Short interest −18.0% to 1.86M shares. 7.6 days to cover, ≈6.4% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdADD162,000$2.1M
Rockefeller Capital Management L.P.TRIM80,143$1.1M
MARSHALL WACE, LLPTRIM72,850$960.2K
ALPS ADVISORS INCADD38,315$505.0K
SEI INVESTMENTS COTRIM33,323$439.2K
UBS Group AGTRIM29,140$384.1K
FRANKLIN TEMPLETON INCTRIM35,168$374.5K
BARCLAYS PLCADD26,949$355.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 23, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 23, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 8, 2026
Rottinghaus Scott T.
Chief Medical Officer
Aug 8, 2026
TAX W/H$19.6K
Mar 11, 2026
Russell Lesley
Director
Mar 11, 2026
AWARD20,000 sh
Mar 11, 2026
CARTER BRUCE L A
Director
Mar 11, 2026
AWARD20,000 sh
Mar 11, 2026
Hata Yujiro S
Director
Mar 11, 2026
AWARD20,000 sh
Mar 11, 2026
Vance Terry
Director
Mar 11, 2026
AWARD20,000 sh
Mar 11, 2026
Peterson Kristine
Director
Mar 11, 2026
AWARD20,000 sh
Mar 11, 2026
FOLETTA MARK G
Director
Mar 11, 2026
AWARD20,000 sh
Feb 12, 2026
Kowalsky Matthew Paul
Chief Legal Officer
Feb 12, 2026
TAX W/H$27.1K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
1,856,510
shares short
-18.0%
vs prior settlement
7.6
days to cover
≈6.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Earnings result
ENTA Q4 2026 Earnings: EPS $-0.81 (-1.4% vs est)
Nov 9, 2026 SEC
Institutional activity in ENTA during Q3 2026 was mixed: two small asset managers added modest positions totaling…
INST-CLUSTER · Impact 3/10
Sep 30, 2026 Inst.
Qube Research & Technologies · ADD
162,000 shares ($2.1M)
Sep 30, 2026 Inst.
Rockefeller Capital Management L.P. · TRIM
80,143 shares ($1.1M)
Aug 8, 2026 Insider
Rottinghaus Scott T. surrendered for taxes 1,467 shares
Chief Medical Officer @ $13.34 ($19.6K)
Jun 23, 2026 Event
Enanta Pharmaceuticals, Inc. v. Pfizer Inc.
Court ruling from Court of Appeals for the Federal Circuit. Docket: 25-1427
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

7 filings · 1 bullish · 2 bearish · 1 mixed · 3 neutral
All ENTA filing & press-release reports (7)